My Cart

Apo-A1

Apo-A1 Overview

English NameApolipoprotein A-IApproved Drugs0
Drugs in Clinical Trials3Target SynonymEpididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
Highest Development StagePhase 2 Clinical
English NameApolipoprotein A-I
Target SynonymEpididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
Approved Drugs0
Drugs in Clinical Trials3
Highest Development StagePhase 2 Clinical

Apo-A1 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
AP1-H5225
Human
HEK293
Human Apo-A1 Protein, His Tag
Add to Cart
Total: 1
  • 1

Apo-A1 Background

ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1 Synonyms

Apolipoprotein A-I,APOA1,MGC117399

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ZerlasiranSLN-360Phase 2 ClinicalSilence Therapeutics PlcAtherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders
Details
Fx-5AFx-5APhase 1 ClinicalKinemed IncCardiovascular Diseases
Details
Recombinant NV-A01 adenovirusPhase 1 ClinicalNanjing Nuowei Biotechnology Co LtdGlioblastoma; Solid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland